



PRESS RELEASE

FOR RELEASE Friday, April 15, 2016

For more information, contact:

Tom Davis, President and CEO, arGentis™ Pharmaceuticals, LLC
901-881-8665

arGentis™ Pharmaceuticals names Ed Henderson Vice President, Business Development and Chief Marketing Officer.

Memphis, TN— arGentis™ Pharmaceuticals, LLC announced today the promotion of Ed Henderson to Vice President. Mr. Henderson has served as Chief Marketing Officer since 2007 and is assuming the additional responsibility as Vice President Business Development.

Ed Henderson has had 30+ successful years in a variety of positions in Specialty Pharmaceuticals Sales and Sales Management. He has been involved in 6 successful new product launches during his career. Mr. Henderson received his B.S. in Biology from The University of Memphis. He presently is a Board Member and Committee Chair for The Highland Hundred of The University of Memphis.

Tom Davis, CEO, stated “we are pleased that Ed has taken on this added responsibility and I look forward to working with him as we continue to develop our unique treatments for autoimmune diseases.

arGentis™ is developing ARG201, a treatment for systemic scleroderma (SSc), an autoimmune disease leading to widespread collagen build up on the skin and within the vascular structures of internal organs, resulting in co-morbidities such as pulmonary hypertension, kidney and gastrointestinal track failure, pulmonary fibrosis and death. SSc is an orphan disease with

approximately 100,000 patients each in the U.S. and Europe.

The mechanism of action of ARG201 is to induce immune tolerance, whereby the body ceases attacking type I collagen, a primary autoantigen in SSc. There are currently no approved therapies for the underlying cause of SSc. ARG201 has been granted orphan drug status in the US by the Federal Drug Administration (FDA) and in the EU by the European Medicines Agency (EMA). There are issued and pending patents for ARG201.

During the Phase IIa clinical trial for ARG201, the investigators detected that approximately 30% of the patients who should have responded to the treatment did not respond. Upon further research, they identified a specific SNP that correlated highly with this response. Research had indicated that this SNP is applicable to other diseases being treated by oral immune tolerance induction. There are patents pending for ROT1.

ROT1 is an identified single nucleotide polymorphism (SNP) that indicates whether a patient will respond to immune tolerance. If ROT1 is present, the patient will not respond to the oral tolerance treatment, hence it is designated “Resistance to Oral Tolerance” or ROT1. It is believed that ROT1 will identify patients in other diseases that may respond to oral tolerance treatments.

arGentis™ is also developing ARG301, utilizing a modified peptide ligand to treat rheumatoid arthritis. The first in man, Phase I clinical trial, is currently being conducted with results expected in 2017. Dr. Andrew Kang stated, “We believe that it will be safe and effective in the treatment of RA patients with less undesirable side effects than current RA treatments.”

Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of the joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. An autoimmune disorder, rheumatoid arthritis occurs when the immune system mistakenly attacks the body's tissues. In addition to causing joint problems, rheumatoid arthritis sometimes can affect other organs of the body — such as the skin, eyes, lungs and blood vessels. Although

rheumatoid arthritis can occur at any age, it usually begins after age 40. The disorder is much more common in women than in men. Treatment focuses on controlling symptoms and preventing joint damage.

arGentis™ Pharmaceuticals, located in Tennessee was established in 2007 to develop pharmaceuticals that address unmet medical needs. The mission of arGentis™ is to develop and commercialize treatments to improve the health and quality of life of the targeted patient groups and provide a fair return to our investors. The current focus is on autoimmune diseases treated primarily by Rheumatologists.